151 related articles for article (PubMed ID: 30568177)
1. Advances in prediction for ovarian cancer treatment stratification.
Oza AM
Nat Rev Clin Oncol; 2019 Feb; 16(2):75-76. PubMed ID: 30568177
[No Abstract] [Full Text] [Related]
2. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
Gallotta V; Conte C; D'Indinosante M; Capoluongo E; Minucci A; De Rose AM; Ardito F; Giuliante F; Di Giorgio A; Zannoni GF; Fagotti A; Margreiter C; Scambia G; Ferrandina G
Eur J Surg Oncol; 2019 Nov; 45(11):2096-2102. PubMed ID: 31227342
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine.
Wethington SL; Wahner-Hendrickson AE; Swisher EM; Kaufmann SH; Karlan BY; Fader AN; Dowdy SC
Gynecol Oncol; 2021 Oct; 163(1):11-13. PubMed ID: 34391577
[No Abstract] [Full Text] [Related]
4. Rucaparib Approved for Ovarian Cancer.
Cancer Discov; 2017 Feb; 7(2):120-121. PubMed ID: 28057616
[TBL] [Abstract][Full Text] [Related]
5. Correspondence on 'Survival outcomes in patients with
Verit FF; Demirkiran F
Int J Gynecol Cancer; 2023 Dec; 33(12):1988. PubMed ID: 37730730
[No Abstract] [Full Text] [Related]
6. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
7. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
8. First-line PARP inhibition in ovarian cancer - standard of care for all?
Banerjee SN; Lord CJ
Nat Rev Clin Oncol; 2020 Mar; 17(3):136-137. PubMed ID: 32051558
[No Abstract] [Full Text] [Related]
9. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
11. Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
Steffensen KD; Adimi P; Jakobsen A
Int J Gynecol Cancer; 2017 Nov; 27(9):1842-1849. PubMed ID: 28763368
[TBL] [Abstract][Full Text] [Related]
12. Olaparib (Lynparza) for advanced ovarian cancer.
Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702
[No Abstract] [Full Text] [Related]
13. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
Stewart J; George A; Banerjee S
Expert Rev Anticancer Ther; 2018 Oct; 18(10):947-958. PubMed ID: 30092674
[TBL] [Abstract][Full Text] [Related]
14. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
Tsibulak I; Wieser V; Degasper C; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Marth C; Fiegl H; Zeimet AG
Br J Cancer; 2018 Sep; 119(6):683-692. PubMed ID: 30111871
[TBL] [Abstract][Full Text] [Related]
16. Talazoparib for BRCA-mutated advanced breast cancer.
Gunjur A
Lancet Oncol; 2018 Oct; 19(10):e511. PubMed ID: 30146245
[No Abstract] [Full Text] [Related]
17. Myelodysplastic Syndrome After Olaparib Treatment in Heavily Pretreated Ovarian Carcinoma.
Sari M; Saip P
Am J Ther; 2019; 26(5):e632-e633. PubMed ID: 30212381
[No Abstract] [Full Text] [Related]
18. Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer.
Wright KM
Oncology (Williston Park); 2020 May; 34(5):175. PubMed ID: 32644177
[TBL] [Abstract][Full Text] [Related]
19. The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Domchek SM
Clin Adv Hematol Oncol; 2018 May; 16(5):330-332. PubMed ID: 29851928
[No Abstract] [Full Text] [Related]
20. Niraparib Slows Ovarian Cancer Progression.
Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
